Modified epidermal growth factor receptor (EGFR)-bearing liposomes (MRBLs) are sensitive to EGF in solution

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Biology

Background:

• Cancers frequently overexpress epidermal growth factor (EGF) to drive cell proliferation and metastasis.
• Existing targeted drug carriers lack sensitivity to aberrant growth factor levels.
• Development of novel drug delivery systems responsive to tumor microenvironments is crucial.

Purpose of the Study:

• To engineer liposomes sensitive to elevated EGF concentrations.
• To investigate the drug release kinetics of modified liposomes in response to EGF.
• To assess the functionality of modified EGF receptors on liposomes.

Main Methods:

• Liposomes were modified with EGF receptors covalently crosslinked to specific molecules (p-toluic acid or methyl-PEO(4)-NHS ester), creating MRBLs.
• EGF-induced dimerization and binding of modified EGF receptors were evaluated.
• Drug release rates from MRBLs were measured in the presence and absence of EGF.

Main Results:

• MRBLs demonstrated an increased rate of encapsulated drug release when EGF was present in solution.
• Modified EGF receptors on MRBLs retained specific binding affinity for EGF.
• EGF binding induced dimerization of modified EGF receptors, enhancing MRBL permeability.

Conclusions:

• MRBLs are sensitive to EGF in solution, indicating potential for targeted drug delivery.
• The EGF-induced dimerization of modified receptors increases liposome permeability, facilitating drug release.
• This approach offers a novel strategy for developing EGF-sensitive nanocarriers for cancer therapy.